I do. I have a core position and occasionally buy and sell covered calls to capture some $$$. All biotechs are risky, but from what I hear pona is the real deal and the side effect complaints are rather overdone.
Admittedly I'd be less happy if ARIA was bought out. They actually have an inkling of an R&D department which is important for sustainability. ONXX plays (imo) a tougher game of in-licensing, and sometimes a bad purchase can really hammer a stock like ONXX for a long time.